AtriCure, Inc. (ATRC) EPS Estimated At $-0.22

October 14, 2018 - By Peter Kolinski

AtriCure, Inc. (NASDAQ:ATRC) LogoInvestors sentiment increased to 1.38 in Q2 2018. Its up 0.60, from 0.78 in 2018Q1. It is positive, as 7 investors sold AtriCure, Inc. shares while 30 reduced holdings. 13 funds opened positions while 38 raised stakes. 28.28 million shares or 5.97% more from 26.69 million shares in 2018Q1 were reported.
Us Comml Bank De has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Legal And General Grp Inc Incorporated Plc reported 5,312 shares stake. Alphaone Services Lc holds 189,560 shares. Metropolitan Life Insur invested in 11,294 shares or 0% of the stock. Ameriprise Financial Incorporated holds 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC) for 109,861 shares. 4,534 were accumulated by Citigroup. Weiss Multi invested in 0.01% or 15,000 shares. Emerald Advisers Incorporated Pa owns 498,586 shares for 0.51% of their portfolio. Moreover, Prelude Capital Mgmt Limited Co has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). Neuberger Berman Group Llc stated it has 0.02% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). Barclays Public Ltd holds 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC) for 13,240 shares. Financial Bank Of Mellon Corporation stated it has 248,516 shares or 0% of all its holdings. California State Teachers Retirement Systems owns 51,315 shares. Utd Capital Fincl Advisers Ltd accumulated 20,004 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 2,044 shares.

Since May 7, 2018, it had 0 insider buys, and 4 sales for $493,930 activity. Collar Mark A had sold 2,090 shares worth $52,250. $228,200 worth of stock was sold by Krell Elizabeth D on Monday, May 7.

Analysts expect AtriCure, Inc. (NASDAQ:ATRC) to report $-0.22 EPS on November, 7.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.22 EPS. After having $-0.19 EPS previously, AtriCure, Inc.’s analysts see 15.79 % EPS growth. The stock increased 3.67% or $1.1 during the last trading session, reaching $31.11. About 446,775 shares traded or 105.47% up from the average. AtriCure, Inc. (NASDAQ:ATRC) has risen 68.55% since October 14, 2017 and is uptrending. It has outperformed by 52.93% the S&P500.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Among 4 analysts covering Atricure (NASDAQ:ATRC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Atricure had 8 analyst reports since April 27, 2018 according to SRatingsIntel. Stifel Nicolaus maintained the shares of ATRC in report on Friday, April 27 with “Buy” rating. On Friday, April 27 the stock rating was maintained by Needham with “Buy”. The stock of AtriCure, Inc. (NASDAQ:ATRC) has “Buy” rating given on Tuesday, October 9 by Canaccord Genuity. Needham maintained it with “Buy” rating and $3200 target in Monday, June 18 report. The stock of AtriCure, Inc. (NASDAQ:ATRC) has “Buy” rating given on Wednesday, June 27 by Stifel Nicolaus. The rating was maintained by Needham on Wednesday, June 27 with “Buy”. As per Wednesday, June 27, the company rating was maintained by Canaccord Genuity.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $1.18 billion. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

More important recent AtriCure, Inc. (NASDAQ:ATRC) news were published by: which released: “AtriCure announces pricing of common stock” on October 05, 2018, also published article titled: “These Cincinnati stocks took the biggest hit amid Dow’s worst loss since February”, published: “Why Chefs’ Warehouse, SMART Global Holdings, and AtriCure Jumped Today” on October 05, 2018. More interesting news about AtriCure, Inc. (NASDAQ:ATRC) was released by: and their article: “Report: Developing Opportunities within Agree Realty, Lattice Semiconductor, American Outdoor Brands, Schneider …” with publication date: October 12, 2018.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: